Gemtuzumab ozogamicin (GO) consists of a humanized anti-CD33 monoclonal antibody linked to calicheamicin, a potent anti-tumor antibiotic. Because approximately 90% of patients with acute myeloid leukemia (AML) have myeloid blasts that express CD33 antigen, 1 GO is an attractive agent to treat AML. In the United States, GO is formulated and marketed as Mylotarg and is approved as monotherapy for patients 460 years of age with a first relapse of AML who are ineligible for other cytotoxic therapies. 2 A Medical Research Council trial in younger adults indicated that the addition of GO (3 mg/m 2 on day 1) to induction chemotherapy reduced the risk of relapse (37 vs 52% at 3 years) without significantly increasing toxicity, thus resulting in a significantly better disease-free survival in the GO arm (51 vs 40% at 3 years). 3 After binding to the CD33 antigen on the surface of myeloid cells, the GO-CD33 complex is internalized and calicheamicin is released. By binding to the DNA minor groove in a sequencespecific manner, calicheamicin causes DNA double-strand breaks and cell killing. 4 Thus, the binding of GO to cell-surface CD33 and subsequent internalization is critical for its antileukemic effect.
In a recent study of patients with relapsed AML who received treatment with GO, significantly higher mean levels of CD33 expression and lower P-glycoprotein activity were observed in responders compared with non-responders. 5 However, other studies have failed to demonstrate a significant impact of CD33 expression of AML blasts on response to GO. 6 Further, pharmacokinetic studies with GO have reported large inter-subject variability in both pediatric and adult patients. 7, 8 In the present study, we undertook a comprehensive analysis of CD33 expression, including polymorphisms in the CD33 gene, and correlated the results to GO response as measured by changes in minimal residual disease (MRD) levels.
We sequenced the complete coding region of the CD33 gene from the genomic DNA of 22 pediatric AML patients who were enrolled on the St Jude AML02 protocol. Details of the multicenter AML02 trial have recently been presented. 9 Briefly, patients were randomly assigned to receive high-dose or lowdose cytarabine (A), daunorubicin (D) and etoposide (E) as Induction I (combined therapy, ADE); all subsequent therapy was risk-adapted. MRD was monitored by flow cytometry as previously described. 10 MRD positivity was defined as 0.1% or more cells with a leukemia-associated immunophenotype among bone-marrow mononuclear cells. Initially, patients with no response (NR, X25% bone-marrow blasts) to Induction I received low-dose ADE þ GO (GO; 3 mg/m 2 ; n ¼ 8) as Induction II, whereas all others received ADE. Because ADE þ GO was effective in reducing tumor burden in patients with NR to Induction I and was well-tolerated, the protocol was amended in February 2005 to expand the use of ADE þ GO to patients with X1% MRD after Induction I. Five patients received ADE þ GO because of NR to induction I, whereas three patients received ADE þ GO because of MRD levels X1%. Patients who were MRD þ after two courses of induction therapy and who have not previously received GO were given GO, 6 mg/m 2 as a single agent, before consolidation chemotherapy or stem cell transplantation (n ¼ 14). Thus all 22 patients included in the present study received GO, either as single agent (n ¼ 14) or in combination with ADE (n ¼ 8). The MRD levels were measured before (ranging from days 1 to 9) and after treatment (between days 11 and 20) with GO. 10 The study design and investigations are approved by the St Jude Children's Research Hospital Institutional Review Board. Written informed consent and assent were obtained from patients, parents/guardians, as appropriate, before enrollment in the study.
We used therapy-stratified permutation tests to explore the association of change in MRD with other variables. Each analysis was stratified according to whether or not patients received ADE in combination with their GO therapy. An MRDchange variable was computed by subtracting post-GO MRD from pre-GO MRD and dividing this result by pre-GO MRD. Negative values indicate a decrease in MRD during GO treatment. To measure the association of MRD change with clinical variables, we computed the Wilcoxon rank-sum or Kruskal-Wallis statistics within each stratum and determined a weighted average of the statistics from the two strata. The weights were proportional to sample size. The association of MRD change with genotype was measured with weighted average of Spearman correlation coefficients of MRD change with the number of copies of a specific allele. The significance of the averaged statistics was determined by 10 000 stratified permutations of MRD-change variable. We used the classical Wilcoxon rank-sum test to examine the association of MRD change with therapy (GO alone vs ADE þ GO). For each polymorphism, the classical Spearman correlation was used to examine the association of CD33 expression levels with the number of alleles. All tests are two-sided; no multiple testing adjustments were used. The analysis was performed using an exact routine implemented in R software.
Among the 22 patients studied, 14 had less than 0.1% residual disease following treatment with GO and five had between 0.1 and 0.6% residual disease (Figure 1b) . The median and upper quartiles of the MRD-change variable were À0.998 and À0.972, respectively. However, three patients had a very poor response. Two of them had an increase in MRD (patient no. 1, 0.0234-40.188, MRD change ¼ 7.03; patient no. 2, 0.00264-40.0258, MRD change ¼ 8.77) and one with slight decrease (0.0414-40.0181, MRD change ¼ À0.56). The MRD change was not associated with initial induction arm, race, combination of GO with ADE, risk group, karyotype or FAB (P40.39 for each comparison).
Data on CD33 transcript expression as measured by Affymetrix 133 GeneChip in leukemic cells obtained at diagnosis were available for 15 patients. There was no significant association between MRD change and CD33 expression (P ¼ 0.80). In addition, we did not observe significant evidence of an association of MRD change with flow-cytometric measurements of the percentage of blasts expressing CD33 protein (P ¼ 0.23). The three non-responders had similar expression of CD33 (measured in either assay). There was no significant relation between GO response and ABCB1 (Pgp1) transcript levels measured in the 15 patients studied for global gene expression by micro array (P ¼ 0.55).
Sequencing of CD33-coding region in 22 AML patients identified eight polymorphisms (Table 1) . However, only Val14Ala, Arg69Gly, Arg304Gly, Ser305Pro and a 3 0 -UTR single nucleotide polymorphism occurred with a minimum allele frequency of greater than 10%.
We determined the association of the genotype of each of the CD33 single nucleotide polymorphisms with changes in MRD during treatment with GO. None of the single nucleotide polymorphisms were significantly associated with CD33 expression levels (P40.34 for each polymorphism). We found that the number of T alleles of rs12459419 has a significant positive association with the MRD-change variable (P ¼ 0.024), with increasing number of T alleles associated with a poorer response to GO-containing regimens (either alone or in combination with ADE) (Figure 1a) . None of the other seven polymorphisms were significantly associated with change in MRD during treatment with GO (P40.35 for each polymorphism). MRD levels in each patient before and after GO-containing regimens are shown in Figure 1b . Out of five patients homozygous for rs12459419 (Val14Val), two demonstrated an increase in MRD and one had very little change in MRD (Figure 1b) . Interestingly, we observed that all three AML Letters to the Editor patients with poor MRD response to GO (MRD levels 40.01) were homozygous TT (Val14Val) for the rs12459419 variant (allele frequency 100%), whereas only 2 of 19 (11%) patients with response to GO (MRD levels o0.01) were homozygous TT. The C4T allele of rs12459419 results in an Ala (codon GCC) to Val (codon GTC) amino-acid change at codon 14 in the protein. The Ala4Val change occurs on the surface of the protein and is present within the signal peptide (amino acid 1-17). Furthermore, the SIFT software (Sorting Intolerant From Tolerant, http://www.blocks.fhcrc.org/sift/SIFT.html) predicts the Val14Ala change to affect the protein function with a score of 0.04. SIFT shows functional significance of aminoacid substitution based on sequence homology and physical properties of the amino acids. This provides a plausible biological explanation for the observed association described above. This amino-acid change might affect the CD33 targeting or compartmentalization or protein structure, which could result in aberrant recognition by GO or internalization of the complex. In this regard, the mRNA level and percentage of CD33-positive cells do not associate with MRD change in this study.
Although the sample size is small, this is the first report exploring and demonstrating an association between coding polymorphisms in CD33 with response to GO. Further confirmation of these results in a larger and independent cohort of AML patients as well as molecular biological studies to functionally characterize these coding polymorphisms are needed and are planned in our laboratory. 
